Filtered By:
Management: Food and Drug Administration (FDA)

This page shows you your search results in order of date. This is page number 3.

Order by Relevance | Date

Total 35 results found since Jan 2013.

Synergistic anti‐myeloma activity of the proteasome inhibitor marizomib and the IMiD® immunomodulatory drug pomalidomide
Abstract The proteasome inhibitor bortezomib is an effective therapy for the treatment of relapsed and refractory multiple myeloma (RRMM); however, prolonged treatment can be associated with toxicity, peripheral neuropathy and drug resistance. Our earlier studies showed that the novel proteasome inhibitor marizomib is distinct from bortezomib in its chemical structure, mechanisms of action and effects on proteasomal activities, and that it can overcome bortezomib resistance. Pomalidomide, like lenalidomide, has potent immunomodulatory activity and has been approved by the US Food and Drug Administration for the treatment o...
Source: British Journal of Haematology - October 12, 2015 Category: Hematology Authors: Deepika S. Das, Arghya Ray, Yan Song, Paul Richardson, Mohit Trikha, Dharminder Chauhan, Kenneth C. Anderson Tags: Research Paper Source Type: research

Current wound healing procedures and potential care.
Abstract In this review, we describe current and future potential wound healing treatments for acute and chronic wounds. The current wound healing approaches are based on autografts, allografts, and cultured epithelial autografts, and wound dressings based on biocompatible and biodegradable polymers. The Food and Drug Administration approved wound healing dressings based on several polymers including collagen, silicon, chitosan, and hyaluronic acid. The new potential therapeutic intervention for wound healing includes sustained delivery of growth factors, and siRNA delivery, targeting microRNA, and stem cell thera...
Source: Appl Human Sci - January 13, 2015 Category: Physiology Authors: Dreifke MB, Jayasuriya AA, Jayasuriya AC Tags: Mater Sci Eng C Mater Biol Appl Source Type: research

Current wound healing procedures and potential care
Publication date: 1 March 2015 Source:Materials Science and Engineering: C, Volume 48 Author(s): Michael B. Dreifke , Amil A. Jayasuriya , Ambalangodage C. Jayasuriya In this review, we describe current and future potential wound healing treatments for acute and chronic wounds. The current wound healing approaches are based on autografts, allografts, and cultured epithelial autografts, and wound dressings based on biocompatible and biodegradable polymers. The Food and Drug Administration approved wound healing dressings based on several polymers including collagen, silicon, chitosan, and hyaluronic acid. The new potentia...
Source: Materials Science and Engineering: C - January 5, 2015 Category: Materials Science Source Type: research

Curcumin-induced Aurora-A suppression not only causes mitotic defect and cell cycle arrest but also alters chemosensitivity to anticancer drugs
Abstract: Overexpression of oncoprotein Aurora-A increases drug resistance and promotes lung metastasis of breast cancer cells. Curcumin is an active anticancer compound in turmeric and curry. Here we observed that Aurora-A protein and kinase activity were reduced in curcumin-treated human breast chemoresistant nonmetastatic MCF-7 and highly metastatic cancer MDA-MB-231 cells. Curcumin acts in a similar manner to Aurora-A small interfering RNA (siRNA), resulting in monopolar spindle formation, S and G2/M arrest, and cell division reduction. Ectopic Aurora-A extinguished the curcumin effects. The anticancer effects of curcu...
Source: The Journal of Nutritional Biochemistry - February 7, 2014 Category: Biochemistry Authors: Ching-Shiun Ke, Hsiao-Sheng Liu, Cheng-Hsin Yen, Guan-Cheng Huang, Hung-Chi Cheng, Chi-Ying F. Huang, Chun-Li Su Tags: Research Articles Source Type: research

Synthetic Lethal Interaction between AKT and TXNRD1
The objective of this study is to identify the genes or pathways that can be targeted to overcome the resistance of non–small cell lung carcinoma (NSCLC) to the AKT inhibitor MK2206, which is currently being evaluated in phase I and II clinical trials. Using a genome-wide siRNA library screening and biologic characterization, we identified that inhibition of thioredoxin reductase-1 (TXNRD1), one of the key antioxidant enzymes, with siRNAs or its inhibitor, auranofin, sensitized NSCLC cells to MK2206 treatment in vitro and in vivo. We found that simultaneous inhibition of TXNRD1 and AKT pathways induced robust reactive ox...
Source: Cancer Research - September 2, 2013 Category: Cancer & Oncology Authors: Dai, B., Yoo, S.-Y., Bartholomeusz, G., Graham, R. A., Majidi, M., Yan, S., Meng, J., Ji, L., Coombes, K., Minna, J. D., Fang, B., Roth, J. A. Tags: Therapeutics, Targets, and Chemical Biology Source Type: research